Safety Policies & Visitor Guidelines |
Appointments & Scheduling |
Schedule a COVID vaccine appointment:
call us 8am to 5pm, Monday through Friday, at 267-758-4902.
Adults (18-65), Geriatrics (65+)
Adults (18-65), Geriatrics (65+)
Perelman Center for Advanced Medicine
West Pavilion, 2nd Floor
3400 Civic Center Boulevard
Philadelphia, PA 19104
A facility of the Hospital of the University of Pennsylvania
Penn Medicine Radnor
Floor 2, Suite 200 North
145 King of Prussia Road
Radnor, PA 19087
The Patient Satisfaction Rating is an average of all responses to the care provider related question shown below from a 3rd party vendor, Press Ganey and as of 7/01/21, our internal platform, PMX Feedback. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.
neuroendocrine tumors and esophagogastric cancer
Lee H, Eads JR, Pryma DA: 68Ga-DOTATATE positron emission tomography-computed tomography quantification predicts response to somatostatin analog therapy in gastroenteropancreatic neuroendocrine tumors Oncologist 26 (1): 21-29,2021.
Eads JR, Krishnamurthi SS, Saltzman J, Bokar JA, Savvides P, Meropol NJ, Gibbons J, Koon H, Sharma N, Pink JJ, Xu Y, Beumer JH, Kane D, Rodal MB, Riendeau J, Fu P, Gerson SL, Dowlati A: Phase I clinical trial of temozolomide and methoxyamine (TRC-102), an inhibitor of base excision repair, in patients with advanced solid tumors Investigational New Drugs : 2021.
Halperin DM, Johnson ML, Chan JA, Hart LL, Cook N, Patel VM, Schlechter BL, Cave J, Dowlati A, Blaszkowsky LS, Meyer T, Eads JR, Culp D, Dridsciukaite K, Mei L, Bilodeau, Bloss J, Kulke MH: The safety and efficacy of PEN-221 somatostatin analog (SSA)-DM1 conjugate in patients with advanced GI mid-gut neuroendocrine tumor: phase 2 results ASCO Annual Meeting, Journal of Clinical Oncology : 2021.
Eads JR, Graham N, Catalano PJ, Gibson MK, Rajdev L, Khullar O, Lin SH, Gatsonis C, Wistuba II, Sanjeevaiah A, Benson AB, Bahary N, Spencer KR, Saba NF, Hamilton SR, Staley CA, Chakravarthy B, Fisher GA, Wong TZ, O'Dwyer PJ: A phase II/III study of perioperative nivolumab and ipilimumab in patients with locoregional esophageal and gastroesophageal junction adenocarcinoma: results of a safety run in-a trial of the ECOG-ACRIN cancer research group (EA2174) ASCO Annual Meeting, Journal of Clinical Oncology : 2021.
Kipnis ST, Hung M, Kumar S, Heckert JM, Lee H, Bennett B, Soulen MC, Pryma DA, Mankoff DA, Metz DC, Eads JR, Katona BW: Laboratory, clinical, and survival outcomes associated with peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors JAMA Network Open : 2021.
Dreyfuss A, Barsky A, Wileyto EP, Eads JR, Kucharczuk J, Williams N, Karasic T, Metz J, Ben-Josef E, Plastaras J, Wojcieszynski A: The efficacy and safety of definitive confurrent chemoradiotherapy for non-operable esophageal cancer Cancer Medicine : 2021.
Goyal L, Sirard C, Schrag M, Kagey MH, Eads JR, Stein S, El-Khoueiry A, Manji G, Abrams T, Khorana AA, Midsad R, Mahalingam D, Zhu AX, Duda DG: Phase I and biomarker study of anti-dickkopf-1 monoclonal antibody DKN-01 in combination with gemcitabine/cisplatin in advanced biliary tract cancer Clinical Cancer Research 26 (23): 6158-6167,2020.
Zhao Y, Feng X, Chen Y, Selfridge JE, Gorityala S, Du Z, Wang JM, Hao Y, Cioffi G, Conlon RA, Barnholtz-Sloan JS, Saltzman J, Krishnamurthi SS, Vinayak S, Veigl M, Xu Y, Bajor DL, Markowitz SD, Meropol NJ, Eads JR, Wang Z: 5-fluorouracil enhances the anti-tumor activity of the glutaminase inhibitor CB-839 against PIK3CA-mutant colorectal cancers Cancer Research 80 (21): 4815-4827,2020.
Eads JR, Reidy-Lagunes D, Soares HP, Chan JA, Anthony LB, Halfdanarson TR, Naraev BG, Wolin EM, Halperin DM, Li D, Pommier RF, Zacks JS, Morse MA, Metz DC; from the Carcinoid Syndrome Control Collaborative: Differential diagnosis of diarrhea in patients with neuroendocrine tumors Pancreas 49 (9): 1123-1130,2020.
Halfdanarson TR, Strosberg JR, Tang L, Bellizzi AM, Bergsland EK, O'Dorisio TM, Halperin DM, Fishbein L, Eads JR, Hope TA, Singh S, Salem R, Metz DC, Naraev BG, Reidy-Lagunes DL, Howe JR, Pommier RF, Menda Y, Chan JA: The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and medical management of pancreatic neuroendocrine tumors Pancreas 49 (7): 863-881,2020.
Perelman Center for Advanced Medicine 10th Floor South Pavilion
Patient appointments: 800-789-7366